[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thymic-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thymic-tumors":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":40,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100598488","an-international-study-on-pediatric-patients-with-rare-tumors-100598488",false,"NCT07072143","An International Study on Pediatric Patients With Rare Tumors.","The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.","PARTNER","Inclusion Criteria:\n\n* Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and\u002For treated in a participating country\u002Fcenter.\n* Written informed consent from the patient and\u002For the parent\u002Flegal guardian\n\nExclusion Criteria:\n\n* Absence of Written informed consent from the patient and\u002For the parent\u002Flegal guardian","ALL","0 Years","18 Years",{"count":21,"type":22},6250,"ESTIMATED","OBSERVATIONAL","The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Paraganglioma\u002F Phaeochromocytoma","Melanoma and Other Malignant Neoplasms of Skin","Gastrointestinal Stromal Tumor (GIST)","Adrenocortical Tumor","Pancreatic Tumors","Esthesioneuroblastoma, Olfactory","Mesothelioma","Nasopharyngeal Carcinoma (NPC)","NUT Carcinoma","Pleuropulmonary Blastoma","Salivary Gland Tumors","Thymic Tumors","Thyroid Carcinoma","Appendiceal Cancers",[41,42,43,44,45],"children","rare tumors","very rare tumors","adolescents","PARTNER Study","RECRUITING","2025-07-16",{"date":49,"type":50},"2025-07-18","ACTUAL",{"date":52,"type":50},"2025-01-25",{"date":54,"type":22},"2049-06-06",{"name":56,"class":57},"Azienda Ospedaliera di Padova","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":5},"100491803","phase-2-a-study-of-kc1036-in-patients-with-advanced-thymic-tumors-100491803","NCT05683886","A Study of KC1036 in Patients with Advanced Thymic Tumors","A Single-arm, Open, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of KC1036 in the Patients with Advanced Recurrent or Metastatic Thymic Tumors","Inclusion Criteria:\n\n* Patients with thymoma or thymic carcinoma confirmed by cytologically or histologically (WHO Classification of Thoracic Tumors 5th ed), including all pathological subtypes;\n* Patients with advanced recurrent, unresectable and\u002For metastatic thymic tumor as defined by the Masaoka-Koga stage;\n* Subsequent relapse of disease following first-line systemic chemotherapy;\n* Patients with at least one measurable lesion as defined by RECIST V1.1; Measurable lesions located within the radiation field of previous radiotherapy or after local treatment can also be selected as target lesions if progression is confirmed.\n* Eastern Cooperative Oncology Group performance status score of 0 or 1;\n* Life expectancy \\> 12 weeks;\n* Adequate organ and marrow function;\n* Patients should participate in the study voluntarily and sign informed consent.\n\nExclusion Criteria:\n\n* Patients with thymus neuroendocrine tumors;\n* Any patient who is known to have central nervous system (CNS) metastasis or imaging shows a risk of CNS metastasis;\n* Previous (within the last 5 years) or current malignancies at other sites;\n* Gastrointestinal abnormalities;\n* Cardiovascular and cerebrovascular diseases;\n* Patients who have previous treatment with small molecule VEGFR-TKI (except patients whose treatment cycle is less than 2 weeks due to intolerance or other reasons); Patients who have previous treatment with PD-1 \u002F PD-L1 antibody combined with small molecule VEGFR-TKI;\n* Involved in other clinical trials within 4 weeks before enrollment; Prior anti-tumor therapies with chemotherapy, cytotherapy, immunotherapy, operation (Interventional therapy excepted) within 4 weeks 4 weeks before enrollment; Prior radiotherapy (palliative radiotherapy excepted) within 2 weeks; Prior small-molecule targeted therapy within 2 weeks or 5 half-lives.\n* Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE V5.0 grade 0 or 1 with the exception of alopecia;\n* Skin wound, surgical site, wound site, mucous membrane severe ulcer or fracture comfirmed as having not recovered;\n* Uncontrolled mass pleural effusion, ascites, and pericardial effusion;\n* Active autoimmune diseases: Myasthenia gravis, pure red cell aplastic anemia, systemic lupus erythematosus, inflammatory bowel disease, etc;\n* Need immunosuppressive agents or hormone therapy for immunosuppression, , and still need immunosuppressive therapy within 2 weeks before enrollment;\n* Active bacterial, viral or fungal infection; Fever of unknown cause (\\> 38.5℃) occurred within 2 weeks before enrollment;\n* Patients who are positive for both Hepatitis B surface antigen (HBsAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) quantification results; Patients who are positive for both hepatitis C virus antibody (HCAB) and hepatitis C virusribonucleic acid (HCV-RNA) quantification results; Patients who are positive for human immunodeficiency virus (HIV);\n* Pregnant or lactating women;\n* Patients who do not take contraception during the study period and within 6 months after the study;\n* Patients with insufficient compliance as evaluated by investigator;\n* The investigator believes that it is not suitable to patient in this clinical trial.","75 Years",{"count":68,"type":22},30,"INTERVENTIONAL",[71],"PHASE2","This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.",[37],"2024-10-15",{"date":76,"type":50},"2024-10-17",{"date":78,"type":50},"2023-02-22",{"date":80,"type":22},"2026-02",{"name":82,"class":83},"Beijing Konruns Pharmaceutical Co., Ltd.","INDUSTRY"]